BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1506 related articles for article (PubMed ID: 31957122)

  • 21. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
    Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L
    Eur Urol Oncol; 2024 Jun; 7(3):544-552. PubMed ID: 38061976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
    Lopci E; Lazzeri M; Colombo P; Casale P; Buffi NM; Saita A; Peschechera R; Hurle R; Marzo K; Leonardi L; Morenghi E; Balzarini L; Disconzi L; Guazzoni G; Chiti A; Lughezzani G
    Urol Int; 2023; 107(5):433-439. PubMed ID: 36724746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
    BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Findings in 1,123 Men with Preoperative
    Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
    J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
    Geboers B; Meijer D; Counter W; Blazevski A; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; O'Neill G; Yuen C; Vis AN; van Leeuwen PJ; Ho B; Liu V; Lee J; Donswijk ML; Oprea-Lager D; Scheltema MJ; Emmett L; Stricker PD
    BJU Int; 2024 Apr; 133 Suppl 4():14-22. PubMed ID: 37858931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of
    Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
    Qiu DX; Li J; Zhang JW; Chen MF; Gao XM; Tang YX; Zhang Y; Yi XP; Yin HL; Gan Y; Wang GL; Zu XB; Hu S; Cai Y
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2821-2832. PubMed ID: 34860277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Biopsy in Men High Risk for Prostate Cancer:
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study).
    Woo HH; Khanani H; Thompson NJ; Sorensen BJ; Baskaranathan S; Bergersen P; Chalasani V; Dean T; Dias M; Symons J; Wines M; Jain A; Nassour AJ; Tarlinton LC
    Eur Urol Open Sci; 2023 Jan; 47():119-125. PubMed ID: 36601041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head-to-head comparisons of [
    Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
    Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective analysis of clinically significant prostate cancer detection with [
    Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric Magnetic Resonance Imaging,
    Kubihal V; Sharma S; Kumar R; Seth A; Kumar R; Kaushal S; Sarangi J; Gupta R; Das CJ
    Indian J Nucl Med; 2021; 36(4):362-370. PubMed ID: 35125753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [68Ga-PSMA-11 PET/mpMRI for local detection of primary prostate cancer in men with a negative prior biopsy].
    Maurer T; Gesterkamp H; Nguyen N; Westenfelder K; Gschwend JE; Budäus L; Rauscher I; Vag T; Weber W; Eiber M
    Aktuelle Urol; 2021 Apr; 52(2):143-148. PubMed ID: 32854128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous
    Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
    Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
    Bodar YJL; Boevé LMS; van Leeuwen PJ; Baars PC; Nieuwenhuijzen JA; van Haarst EP; Oddens JR; Donswijk ML; van Riel LAMJG; Scheltema MJ; Meijer D; Hendrikse NH; Oprea-Lager DE; Vis AN
    BJU Int; 2023 Dec; 132(6):705-712. PubMed ID: 37620288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.